Amarin Publishes Results of Vascepa (icosapent ethyl) in (REDUCE-IT) Study for the Treatment of Cardiovascular Diseases in JAHA 2022
Shots:
- The (REDUCE-IT) study evaluate the effect of Vascepa vs PBO in 8179 patients aged ≥4.9yrs. with CV disease who have received a PCI & at high risk of stroke, heart attack, or fatal CV event at ~400 clinical sites in 11 countries
- In a new post hoc sub-analysis, patients showed a reduction in the primary & secondary composite EPs of CV death, non-fatal MI & stroke, coronary revascularization, or unstable angina by 34% in patients with a history of PCI
- Additionally, 40% risk reduction of repeat coronary revascularization, robust absolute risk reductions (8.5% & 5.4%) and no. needed to treat (NNT) of 12 & 19 for the 1EPs & 2EPs. The safety results were consistent with the full study cohort
Ref: Globe Newswire | Image: Amarin
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
